BAY 73-4506
Sponsors
Institut Gustave Roussy, Bayer AG, Institut Bergonie, Centre Leon Berard, Centre Hospitalier Regional Universitaire
Conditions
Adult patients with advanced or metastatic solid tumorsNewly diagnosed patients with metastatic (other than lung/pleura metastases only) Ewing sarcomaPatients with bone sarcomas other than chordomaSolid malignant tumorsmetastatic colorectal cancer carcinomawho have no residual disease after their standard treatment sequence.
Phase 1
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma - REGO-INTER-EWING1
RecruitingCTIS2023-503322-39-00
Start: 2023-06-16Target: 26Updated: 2025-02-21
REGOMUNE : A phase I/II study of Regorafenib plus Avelumab in solid tumors
Active, not recruitingCTIS2023-509500-15-00
Start: 2018-05-03Target: 827Updated: 2025-11-21
Phase 2
(22551) A single arm, open-label, multicenter Phase 2 study of regorafenib in participants who have been treated in a previous Bayer-sponsored regorafenib study (monotherapy or combination treatment) that has reached the primary completion endpoint, or main data analysis, or has been stopped prematurely.
Active, not recruitingCTIS2023-507084-19-00
Start: 2024-03-07Target: 5Updated: 2026-01-07
REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer carcinoma
An open-label randomized phase II-III study
Not yet recruitingCTIS2024-516709-22-00
Target: 94Updated: 2025-10-08